Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2021-02-05 Capital/Financing Update
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Capital/Financing Update Classification · 99% confidence The document is dated February 5, 2021, and is titled 'Fresenius SE & Co. KGaA: Release according to Article 50 of the WpHG' (German Securities Trading Act). It specifically announces amendments to the Indenture governing senior notes, particularly modifying reporting requirements within Section 4.10 (Reports) concerning the delivery of annual financial statements and audit reports. This is a formal regulatory announcement concerning debt covenants and reporting obligations, transmitted via DGAP (a service for regulatory announcements). Since it is not the full financial report (10-K or IR) but rather a notice about changes to the terms related to those reports, and it falls under general regulatory disclosure requirements (WpHG Article 50), it best fits the general 'Regulatory Filings' category, as it doesn't specifically match CAP (financing update), LTR (legal), or DIV (dividend). Given the nature of the announcement being a mandatory disclosure under German securities law regarding bond terms, RNS (Regulatory Filings) is the most appropriate general classification.
2021-02-05 English
Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21
Earnings Release Classification · 100% confidence The document is dated February 1, 2021, and is explicitly labeled as an 'Ad-hoc' announcement disclosing 'inside information acc. to Article 17 MAR'. It provides preliminary guidance and updates on expected FY/21 net income due to COVID-19 impacts, specifically mentioning the upcoming release of FY/20 results on February 23, 2021. This is not a full financial report (10-K or IR), nor is it a transcript (CT) or a formal dividend notice (DIV). It is an unscheduled, material update regarding financial outlook, which fits best under the general category for regulatory announcements that convey material, non-scheduled information, or an Earnings Release (ER) if it were a scheduled quarterly release. Since this is an unscheduled update on expected performance and impacts, and it precedes the formal results release, it functions as a pre-release warning or update. However, given the context of MAR Article 17 disclosure (inside information), and the fact that it is not a formal Earnings Release (ER) which typically covers the *past* period's results, the most appropriate classification for a general, material, unscheduled regulatory disclosure that doesn't fit other specific categories is Regulatory Filings (RNS). It is an announcement *about* future earnings expectations, not the formal Earnings Release itself. FY 2021
2021-02-01 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an individual (Dr. Gerd Krick), their position, the nature of the transaction ('Acquisition'), the financial instrument (Share), price, volume, and date. This content directly matches the definition for Director's Dealing.
2021-01-19 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'DGAP-DD: Fresenius SE & Co. KGaA english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This content directly corresponds to the definition of Director's Dealing, which is classified under the code DIRS. The document details the name of the person (Dr. Gerd Krick), their position, the nature of the transaction (Acquisition), the price, volume, and date of the transaction involving company shares.
2021-01-05 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details the name of an individual (Dr. Gerd Krick), their position ('Member of the administrative or supervisory body'), and records an 'Acquisition' of shares, including price and volume, dated 2020-12-29. This content directly matches the definition for Director's Dealing.
2020-12-30 English
Declaration of Conformity of Fresenius SE & Co. KGaA as of December 20, 2020
Governance Information Classification · 99% confidence The document is explicitly titled as a 'Declaration by the Management Board... and the Supervisory Board... on the German Corporate Governance Code pursuant to Section 161 German Stock Corporation Act'. This document details compliance, or lack thereof, with specific recommendations (like B.5, C.2, G.1-G.3, G.6) of the German Corporate Governance Code. This content directly relates to the company's internal rules, board structure, and governance practices, making it a Governance Information document.
2020-12-20 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.